| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 93 | 2016 | 20822 | 1.190 |
Why?
|
| Genes, BRCA1 | 12 | 2013 | 781 | 0.940 |
Why?
|
| DNA, Neoplasm | 14 | 2012 | 1758 | 0.600 |
Why?
|
| Receptors, Estrogen | 11 | 2009 | 2187 | 0.560 |
Why?
|
| NF-kappa B | 5 | 2013 | 2499 | 0.530 |
Why?
|
| Transcription Factor RelA | 1 | 2015 | 275 | 0.480 |
Why?
|
| Receptor, erbB-2 | 23 | 2016 | 2416 | 0.480 |
Why?
|
| Streptothricins | 1 | 2013 | 6 | 0.470 |
Why?
|
| Acetyltransferases | 1 | 2013 | 234 | 0.420 |
Why?
|
| Genes, p53 | 11 | 1998 | 755 | 0.410 |
Why?
|
| Interferons | 1 | 2015 | 706 | 0.410 |
Why?
|
| Breast | 11 | 2015 | 1969 | 0.400 |
Why?
|
| Neoplasm Proteins | 12 | 2013 | 3703 | 0.400 |
Why?
|
| Genes, BRCA2 | 3 | 2013 | 618 | 0.400 |
Why?
|
| Gene Amplification | 10 | 2012 | 1063 | 0.320 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 8 | 2015 | 949 | 0.320 |
Why?
|
| Tumor Suppressor Protein p53 | 12 | 2015 | 2948 | 0.310 |
Why?
|
| Transfection | 6 | 2013 | 5892 | 0.300 |
Why?
|
| DNA Damage | 7 | 2018 | 2432 | 0.300 |
Why?
|
| Gene Expression Regulation, Neoplastic | 18 | 2015 | 8428 | 0.300 |
Why?
|
| Specialties, Surgical | 1 | 2012 | 391 | 0.290 |
Why?
|
| Ovarian Neoplasms | 14 | 2018 | 4838 | 0.270 |
Why?
|
| Ploidies | 4 | 1995 | 281 | 0.270 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 2012 | 2938 | 0.270 |
Why?
|
| Genetic Testing | 5 | 2012 | 3444 | 0.260 |
Why?
|
| Physician's Role | 1 | 2012 | 943 | 0.250 |
Why?
|
| Gene Expression | 11 | 2013 | 7799 | 0.250 |
Why?
|
| Drug Design | 1 | 2009 | 1076 | 0.230 |
Why?
|
| Loss of Heterozygosity | 4 | 2013 | 684 | 0.220 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2006 | 692 | 0.220 |
Why?
|
| Gene Expression Profiling | 11 | 2016 | 9438 | 0.210 |
Why?
|
| Apoptosis | 8 | 2016 | 9727 | 0.210 |
Why?
|
| Proto-Oncogenes | 4 | 1993 | 321 | 0.210 |
Why?
|
| Carcinoma in Situ | 4 | 2010 | 806 | 0.210 |
Why?
|
| BRCA1 Protein | 6 | 2006 | 1149 | 0.210 |
Why?
|
| DNA-Activated Protein Kinase | 2 | 2013 | 117 | 0.190 |
Why?
|
| Cell Division | 9 | 2007 | 4568 | 0.190 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 7 | 2010 | 3920 | 0.190 |
Why?
|
| Proto-Oncogene Proteins | 9 | 2010 | 4554 | 0.190 |
Why?
|
| DNA Repair | 5 | 2016 | 2046 | 0.190 |
Why?
|
| Carcinoma, Bronchogenic | 3 | 1990 | 87 | 0.180 |
Why?
|
| Medical Oncology | 1 | 2012 | 2265 | 0.180 |
Why?
|
| RecQ Helicases | 2 | 2018 | 54 | 0.180 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 3 | 2012 | 890 | 0.170 |
Why?
|
| Sirolimus | 1 | 2006 | 1564 | 0.170 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2009 | 3760 | 0.170 |
Why?
|
| Genetic Counseling | 2 | 2002 | 600 | 0.170 |
Why?
|
| Estradiol | 4 | 2008 | 2020 | 0.170 |
Why?
|
| Neoplasm Staging | 21 | 2015 | 11031 | 0.160 |
Why?
|
| Nuclear Proteins | 6 | 2013 | 5853 | 0.160 |
Why?
|
| Mammary Neoplasms, Animal | 2 | 2012 | 137 | 0.160 |
Why?
|
| Female | 102 | 2018 | 380194 | 0.160 |
Why?
|
| BRCA2 Protein | 6 | 2006 | 794 | 0.160 |
Why?
|
| Platinum Compounds | 1 | 2018 | 96 | 0.150 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2015 | 604 | 0.150 |
Why?
|
| Lymphatic Metastasis | 9 | 2011 | 2924 | 0.150 |
Why?
|
| Signal Transduction | 7 | 2013 | 23403 | 0.150 |
Why?
|
| Cell Transformation, Neoplastic | 6 | 2012 | 2942 | 0.150 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 2011 | 520 | 0.140 |
Why?
|
| Oncogene Proteins | 2 | 2011 | 749 | 0.140 |
Why?
|
| Immunohistochemistry | 14 | 2016 | 11366 | 0.140 |
Why?
|
| Mutation | 19 | 2013 | 29786 | 0.140 |
Why?
|
| Heterozygote | 6 | 2000 | 2804 | 0.140 |
Why?
|
| Humans | 129 | 2018 | 744343 | 0.140 |
Why?
|
| Phosphorylation | 6 | 2016 | 8436 | 0.140 |
Why?
|
| Cell Cycle | 6 | 2004 | 2967 | 0.130 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2015 | 68 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 9 | 2015 | 3616 | 0.130 |
Why?
|
| Transcriptional Activation | 2 | 2005 | 1783 | 0.130 |
Why?
|
| Promoter Regions, Genetic | 6 | 2005 | 5867 | 0.130 |
Why?
|
| Epithelial Cells | 9 | 2015 | 3690 | 0.130 |
Why?
|
| Cell Line, Tumor | 13 | 2015 | 16689 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 7181 | 0.130 |
Why?
|
| Fallopian Tubes | 1 | 2015 | 182 | 0.130 |
Why?
|
| Carcinoma, Small Cell | 3 | 1987 | 420 | 0.130 |
Why?
|
| Carcinoma, Lobular | 3 | 2015 | 484 | 0.120 |
Why?
|
| Cell Line | 11 | 2015 | 15997 | 0.120 |
Why?
|
| Ultraviolet Rays | 3 | 2014 | 1060 | 0.120 |
Why?
|
| Cyclin D1 | 4 | 2005 | 463 | 0.120 |
Why?
|
| Carcinoma, Ductal, Breast | 4 | 2015 | 1101 | 0.120 |
Why?
|
| Stress, Physiological | 2 | 2012 | 1403 | 0.120 |
Why?
|
| Morpholines | 2 | 2016 | 571 | 0.120 |
Why?
|
| Hygromycin B | 1 | 2013 | 11 | 0.120 |
Why?
|
| Puromycin | 1 | 2013 | 44 | 0.120 |
Why?
|
| Neoplasm Metastasis | 6 | 2012 | 4851 | 0.120 |
Why?
|
| Chromosomes, Human, X | 2 | 2006 | 296 | 0.120 |
Why?
|
| Retinoblastoma Protein | 3 | 2015 | 704 | 0.120 |
Why?
|
| Autophagy | 2 | 2012 | 1300 | 0.120 |
Why?
|
| Neomycin | 1 | 2013 | 88 | 0.120 |
Why?
|
| Mitotic Index | 1 | 1993 | 172 | 0.120 |
Why?
|
| Genes, Dominant | 1 | 1996 | 880 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2015 | 538 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2016 | 5172 | 0.110 |
Why?
|
| Cinnamates | 1 | 2013 | 60 | 0.110 |
Why?
|
| Tamoxifen | 4 | 2006 | 981 | 0.110 |
Why?
|
| Cyclin-Dependent Kinases | 2 | 2015 | 671 | 0.110 |
Why?
|
| Gene Silencing | 3 | 2010 | 1538 | 0.110 |
Why?
|
| Pyrrolidinones | 1 | 2013 | 117 | 0.110 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2016 | 2109 | 0.110 |
Why?
|
| Cell Nucleolus | 2 | 2012 | 166 | 0.110 |
Why?
|
| Aminopyridines | 1 | 2016 | 542 | 0.110 |
Why?
|
| Carcinoma | 5 | 2008 | 2375 | 0.110 |
Why?
|
| Oncogene Proteins, Viral | 1 | 1994 | 362 | 0.100 |
Why?
|
| Multiprotein Complexes | 2 | 2016 | 1119 | 0.100 |
Why?
|
| Genomic Instability | 2 | 2016 | 695 | 0.100 |
Why?
|
| RNA, Ribosomal | 1 | 2013 | 246 | 0.100 |
Why?
|
| Transcription Factors | 5 | 1999 | 12208 | 0.100 |
Why?
|
| Keratin-19 | 2 | 2009 | 33 | 0.100 |
Why?
|
| Allelic Imbalance | 1 | 2012 | 77 | 0.100 |
Why?
|
| Antineoplastic Agents | 9 | 2018 | 13695 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 14 | 2001 | 6314 | 0.100 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2009 | 934 | 0.100 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2013 | 440 | 0.100 |
Why?
|
| Phosphoprotein Phosphatases | 2 | 2010 | 337 | 0.100 |
Why?
|
| Neoplasms, Hormone-Dependent | 3 | 2005 | 415 | 0.100 |
Why?
|
| Mammary Glands, Animal | 1 | 2012 | 276 | 0.090 |
Why?
|
| Lung Neoplasms | 9 | 1995 | 13102 | 0.090 |
Why?
|
| Lymph Node Excision | 2 | 2011 | 1261 | 0.090 |
Why?
|
| Cisplatin | 4 | 2013 | 1662 | 0.090 |
Why?
|
| Immunoglobulin A, Secretory | 2 | 1981 | 103 | 0.090 |
Why?
|
| Molecular Sequence Data | 18 | 2006 | 18111 | 0.090 |
Why?
|
| Gene Expression Regulation | 3 | 2005 | 12072 | 0.090 |
Why?
|
| Mutant Proteins | 1 | 2012 | 500 | 0.090 |
Why?
|
| Phyllodes Tumor | 2 | 2006 | 53 | 0.090 |
Why?
|
| Genes, erbB-2 | 4 | 2007 | 162 | 0.090 |
Why?
|
| DNA Helicases | 2 | 2013 | 859 | 0.090 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2012 | 198 | 0.090 |
Why?
|
| Genes, Neoplasm | 1 | 2012 | 376 | 0.090 |
Why?
|
| Genes, ras | 2 | 2007 | 690 | 0.090 |
Why?
|
| Membrane Proteins | 3 | 2012 | 7880 | 0.090 |
Why?
|
| Anoikis | 1 | 2009 | 49 | 0.090 |
Why?
|
| False Positive Reactions | 2 | 2009 | 981 | 0.090 |
Why?
|
| Methylnitrosourea | 2 | 2007 | 29 | 0.090 |
Why?
|
| Breast Diseases | 2 | 1992 | 443 | 0.080 |
Why?
|
| Hyperplasia | 1 | 2012 | 1185 | 0.080 |
Why?
|
| Neoplasms, Basal Cell | 2 | 2006 | 31 | 0.080 |
Why?
|
| Carcinoma, Ductal | 1 | 2009 | 101 | 0.080 |
Why?
|
| Down-Regulation | 2 | 2015 | 3002 | 0.080 |
Why?
|
| Genes, Lethal | 1 | 2009 | 242 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1990 | 417 | 0.080 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2010 | 270 | 0.080 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2016 | 2916 | 0.080 |
Why?
|
| Genomics | 1 | 2004 | 5720 | 0.080 |
Why?
|
| Transcription, Genetic | 5 | 2015 | 7722 | 0.080 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2012 | 2505 | 0.080 |
Why?
|
| Mammography | 5 | 2009 | 2476 | 0.080 |
Why?
|
| Prognosis | 16 | 2015 | 29063 | 0.080 |
Why?
|
| Chromosome Aberrations | 3 | 2013 | 1813 | 0.080 |
Why?
|
| Fibroma | 1 | 2009 | 212 | 0.080 |
Why?
|
| Ki-67 Antigen | 3 | 2016 | 644 | 0.080 |
Why?
|
| Neuregulin-1 | 2 | 2007 | 142 | 0.070 |
Why?
|
| Epithelium | 8 | 1998 | 1679 | 0.070 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2008 | 193 | 0.070 |
Why?
|
| Mice, SCID | 4 | 2016 | 2716 | 0.070 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2011 | 709 | 0.070 |
Why?
|
| Interferon-gamma | 1 | 2015 | 3206 | 0.070 |
Why?
|
| Base Sequence | 17 | 2009 | 12797 | 0.070 |
Why?
|
| RNA, Messenger | 12 | 2012 | 13033 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2010 | 11524 | 0.070 |
Why?
|
| Phthalazines | 1 | 2009 | 363 | 0.070 |
Why?
|
| Estrogens | 3 | 2005 | 1566 | 0.070 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2009 | 730 | 0.070 |
Why?
|
| Immunoglobulin A | 2 | 1981 | 992 | 0.070 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2006 | 205 | 0.070 |
Why?
|
| Fibroadenoma | 1 | 2006 | 43 | 0.070 |
Why?
|
| Intercellular Junctions | 1 | 1987 | 203 | 0.070 |
Why?
|
| DNA | 5 | 2012 | 7301 | 0.070 |
Why?
|
| Animals | 24 | 2016 | 168757 | 0.070 |
Why?
|
| Flavonoids | 3 | 2009 | 443 | 0.070 |
Why?
|
| Telomere | 1 | 2012 | 910 | 0.070 |
Why?
|
| Neoplasms | 3 | 2012 | 21683 | 0.070 |
Why?
|
| Reference Values | 3 | 2009 | 4982 | 0.070 |
Why?
|
| Cluster Analysis | 4 | 2006 | 2715 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 8 | 2009 | 9274 | 0.070 |
Why?
|
| Bronchial Fistula | 1 | 1986 | 85 | 0.070 |
Why?
|
| Cell Proliferation | 4 | 2015 | 10481 | 0.070 |
Why?
|
| Germ-Line Mutation | 3 | 2013 | 1788 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 17 | 3 | 2006 | 437 | 0.060 |
Why?
|
| Bronchi | 4 | 1992 | 840 | 0.060 |
Why?
|
| Pancreatic Fistula | 1 | 1986 | 146 | 0.060 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2005 | 129 | 0.060 |
Why?
|
| Receptors, Progesterone | 1 | 2009 | 1097 | 0.060 |
Why?
|
| DNA-Binding Proteins | 5 | 2014 | 9648 | 0.060 |
Why?
|
| Mastectomy, Segmental | 2 | 2008 | 956 | 0.060 |
Why?
|
| I-kappa B Proteins | 1 | 2005 | 225 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2016 | 3557 | 0.060 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2006 | 1524 | 0.060 |
Why?
|
| Annexin A5 | 1 | 2004 | 103 | 0.060 |
Why?
|
| Disease Progression | 4 | 2010 | 13284 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2010 | 2503 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2007 | 3479 | 0.060 |
Why?
|
| Middle Aged | 31 | 2015 | 213383 | 0.060 |
Why?
|
| DNA Topoisomerases, Type II | 2 | 2001 | 121 | 0.060 |
Why?
|
| Cyclins | 2 | 1996 | 603 | 0.060 |
Why?
|
| Fibrinogen | 1 | 2006 | 894 | 0.060 |
Why?
|
| Sensitivity and Specificity | 5 | 2012 | 14722 | 0.060 |
Why?
|
| Mice | 15 | 2016 | 81183 | 0.050 |
Why?
|
| X Chromosome Inactivation | 1 | 2005 | 224 | 0.050 |
Why?
|
| Cells, Cultured | 7 | 2010 | 19229 | 0.050 |
Why?
|
| Biopsy | 3 | 2009 | 6756 | 0.050 |
Why?
|
| Mice, Inbred NOD | 3 | 2015 | 1878 | 0.050 |
Why?
|
| Cell Survival | 3 | 2009 | 5882 | 0.050 |
Why?
|
| Etoposide | 3 | 2001 | 641 | 0.050 |
Why?
|
| Axilla | 4 | 2011 | 595 | 0.050 |
Why?
|
| Blotting, Western | 4 | 2012 | 5179 | 0.050 |
Why?
|
| Chromatin | 2 | 2013 | 2934 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2008 | 1836 | 0.050 |
Why?
|
| Aged | 22 | 2015 | 163280 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 1995 | 5221 | 0.050 |
Why?
|
| Lymph Nodes | 3 | 2000 | 3474 | 0.050 |
Why?
|
| Proteome | 2 | 2012 | 1799 | 0.050 |
Why?
|
| Spouses | 1 | 2003 | 286 | 0.050 |
Why?
|
| Neoplasm Transplantation | 4 | 2016 | 2085 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2011 | 9239 | 0.050 |
Why?
|
| Southeastern United States | 1 | 2000 | 95 | 0.050 |
Why?
|
| Adult | 24 | 2015 | 214055 | 0.050 |
Why?
|
| Decision Trees | 2 | 2000 | 506 | 0.050 |
Why?
|
| Mice, Nude | 4 | 2013 | 3689 | 0.050 |
Why?
|
| Enzyme Activation | 4 | 2013 | 3701 | 0.050 |
Why?
|
| Chromosome Deletion | 4 | 1996 | 1401 | 0.050 |
Why?
|
| Antigens, Nuclear | 2 | 2012 | 192 | 0.050 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2003 | 560 | 0.040 |
Why?
|
| Predictive Value of Tests | 6 | 2008 | 15076 | 0.040 |
Why?
|
| Carrier Proteins | 4 | 2016 | 5021 | 0.040 |
Why?
|
| Pattern Recognition, Automated | 1 | 2006 | 1005 | 0.040 |
Why?
|
| Transplantation, Heterologous | 6 | 2011 | 2382 | 0.040 |
Why?
|
| Adenocarcinoma | 6 | 2009 | 6364 | 0.040 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 1998 | 1660 | 0.040 |
Why?
|
| Amino Acid Sequence | 5 | 2006 | 13815 | 0.040 |
Why?
|
| Protein Kinases | 1 | 2006 | 1640 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2015 | 3752 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 2 | 1996 | 1097 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2003 | 17446 | 0.040 |
Why?
|
| Macrophages | 1 | 1993 | 5655 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2003 | 3923 | 0.040 |
Why?
|
| Proteomics | 1 | 2012 | 3638 | 0.040 |
Why?
|
| Diagnosis, Differential | 3 | 2009 | 12959 | 0.040 |
Why?
|
| Piperazines | 1 | 2009 | 2488 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2006 | 2203 | 0.040 |
Why?
|
| Piperidines | 2 | 2009 | 1602 | 0.040 |
Why?
|
| Enzyme Inhibitors | 3 | 2000 | 3798 | 0.040 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 1998 | 65 | 0.040 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 1998 | 87 | 0.040 |
Why?
|
| Neoplasms, Second Primary | 1 | 2006 | 1061 | 0.040 |
Why?
|
| Epidermal Growth Factor | 2 | 2001 | 708 | 0.040 |
Why?
|
| Ligands | 1 | 2005 | 3282 | 0.040 |
Why?
|
| DNA Primers | 5 | 2009 | 2892 | 0.040 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2000 | 426 | 0.040 |
Why?
|
| Models, Biological | 4 | 2012 | 9583 | 0.040 |
Why?
|
| Alleles | 4 | 2006 | 6933 | 0.040 |
Why?
|
| Transforming Growth Factor beta | 2 | 1995 | 2007 | 0.040 |
Why?
|
| Exons | 3 | 2010 | 2437 | 0.040 |
Why?
|
| Rats, Inbred WF | 2 | 2007 | 140 | 0.040 |
Why?
|
| Follow-Up Studies | 7 | 2015 | 39050 | 0.040 |
Why?
|
| Flow Cytometry | 4 | 2014 | 5974 | 0.040 |
Why?
|
| Receptor, IGF Type 2 | 1 | 1996 | 35 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 1 | 2007 | 2728 | 0.040 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 2 | 1994 | 222 | 0.040 |
Why?
|
| Estrogen Antagonists | 1 | 1997 | 152 | 0.040 |
Why?
|
| Cell Cycle Proteins | 2 | 2016 | 3462 | 0.030 |
Why?
|
| Lovastatin | 1 | 1996 | 120 | 0.030 |
Why?
|
| Vinblastine | 2 | 2009 | 502 | 0.030 |
Why?
|
| Colorectal Neoplasms | 2 | 2010 | 6773 | 0.030 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 1999 | 241 | 0.030 |
Why?
|
| Eukaryotic Initiation Factors | 1 | 2016 | 92 | 0.030 |
Why?
|
| DNA, Antisense | 1 | 1995 | 46 | 0.030 |
Why?
|
| Aged, 80 and over | 8 | 2015 | 57776 | 0.030 |
Why?
|
| Blotting, Northern | 5 | 1996 | 1581 | 0.030 |
Why?
|
| Transglutaminases | 1 | 1996 | 194 | 0.030 |
Why?
|
| Insulin | 1 | 1990 | 6580 | 0.030 |
Why?
|
| Combined Modality Therapy | 6 | 2007 | 8642 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2005 | 2282 | 0.030 |
Why?
|
| Ovary | 2 | 1996 | 981 | 0.030 |
Why?
|
| Camptothecin | 1 | 1998 | 576 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 8863 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2005 | 1972 | 0.030 |
Why?
|
| Genome, Human | 3 | 2013 | 4420 | 0.030 |
Why?
|
| DNA Methylation | 2 | 2006 | 4286 | 0.030 |
Why?
|
| Pyrimidine Dimers | 1 | 2014 | 18 | 0.030 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1996 | 433 | 0.030 |
Why?
|
| Genetic Markers | 5 | 2004 | 2634 | 0.030 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 1998 | 624 | 0.030 |
Why?
|
| HeLa Cells | 2 | 2012 | 3128 | 0.030 |
Why?
|
| Carcinogens | 2 | 2005 | 466 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2006 | 5097 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2016 | 758 | 0.030 |
Why?
|
| Genital Neoplasms, Female | 1 | 1999 | 523 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 1993 | 6365 | 0.030 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1995 | 798 | 0.030 |
Why?
|
| Receptors, Thyroid Hormone | 1 | 1994 | 202 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2009 | 6234 | 0.030 |
Why?
|
| GTP Phosphohydrolases | 1 | 1996 | 509 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 5 | 2010 | 6171 | 0.030 |
Why?
|
| Cell Growth Processes | 1 | 2013 | 399 | 0.030 |
Why?
|
| Metallothionein | 1 | 1992 | 59 | 0.030 |
Why?
|
| Artificial Intelligence | 1 | 2006 | 2214 | 0.030 |
Why?
|
| Remission Induction | 2 | 2016 | 2386 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 1999 | 1683 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2000 | 1526 | 0.030 |
Why?
|
| Trachea | 2 | 1989 | 1076 | 0.030 |
Why?
|
| DNA, Satellite | 1 | 1992 | 69 | 0.030 |
Why?
|
| Nucleic Acid Hybridization | 2 | 1991 | 1375 | 0.030 |
Why?
|
| RNA Interference | 2 | 2011 | 2889 | 0.030 |
Why?
|
| Point Mutation | 2 | 1996 | 1623 | 0.030 |
Why?
|
| GTP-Binding Proteins | 1 | 1996 | 970 | 0.030 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2012 | 154 | 0.030 |
Why?
|
| Counseling | 1 | 2000 | 1523 | 0.030 |
Why?
|
| Doxorubicin | 4 | 2007 | 2234 | 0.030 |
Why?
|
| S Phase | 1 | 2013 | 423 | 0.030 |
Why?
|
| Reproducibility of Results | 5 | 2007 | 19905 | 0.030 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 1 | 1992 | 45 | 0.030 |
Why?
|
| Calcinosis | 2 | 1992 | 1499 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 1994 | 473 | 0.030 |
Why?
|
| Phenotype | 1 | 2009 | 16365 | 0.030 |
Why?
|
| Cloning, Molecular | 2 | 1994 | 4320 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2002 | 2278 | 0.020 |
Why?
|
| Polyomavirus | 1 | 2012 | 248 | 0.020 |
Why?
|
| Nerve Block | 1 | 1998 | 644 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2012 | 15519 | 0.020 |
Why?
|
| Staining and Labeling | 2 | 1995 | 1100 | 0.020 |
Why?
|
| North Carolina | 2 | 2002 | 315 | 0.020 |
Why?
|
| Mastectomy | 3 | 2008 | 1793 | 0.020 |
Why?
|
| Attitude to Health | 1 | 2000 | 2052 | 0.020 |
Why?
|
| DNA Mutational Analysis | 2 | 2003 | 4186 | 0.020 |
Why?
|
| Intracellular Membranes | 1 | 2011 | 390 | 0.020 |
Why?
|
| Cathepsins | 1 | 2011 | 241 | 0.020 |
Why?
|
| Drug Synergism | 2 | 2007 | 1792 | 0.020 |
Why?
|
| Culture Media | 1 | 1992 | 908 | 0.020 |
Why?
|
| Cyclophosphamide | 3 | 2007 | 2242 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2001 | 2576 | 0.020 |
Why?
|
| Phagosomes | 1 | 2011 | 193 | 0.020 |
Why?
|
| RNA, Neoplasm | 4 | 1995 | 769 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2000 | 1938 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2005 | 14557 | 0.020 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 1997 | 1184 | 0.020 |
Why?
|
| Risk | 3 | 2008 | 9687 | 0.020 |
Why?
|
| 3T3 Cells | 2 | 2002 | 1101 | 0.020 |
Why?
|
| G1 Phase | 3 | 1996 | 415 | 0.020 |
Why?
|
| Ribosomes | 1 | 2013 | 500 | 0.020 |
Why?
|
| Immunoblotting | 2 | 2009 | 1682 | 0.020 |
Why?
|
| Ribonucleoproteins | 1 | 2012 | 381 | 0.020 |
Why?
|
| Decision Making | 1 | 2003 | 3887 | 0.020 |
Why?
|
| Xeroradiography | 1 | 1988 | 6 | 0.020 |
Why?
|
| Postmenopause | 2 | 2008 | 2461 | 0.020 |
Why?
|
| Immunomagnetic Separation | 1 | 2009 | 80 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 1999 | 1956 | 0.020 |
Why?
|
| Enhancer Elements, Genetic | 1 | 1995 | 1341 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 1997 | 2015 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2001 | 3396 | 0.020 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 1993 | 719 | 0.020 |
Why?
|
| High Mobility Group Proteins | 1 | 2009 | 187 | 0.020 |
Why?
|
| Zinc | 1 | 1992 | 684 | 0.020 |
Why?
|
| Bronchoscopy | 2 | 1986 | 862 | 0.020 |
Why?
|
| Retrospective Studies | 8 | 2012 | 77449 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2010 | 460 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2013 | 1094 | 0.020 |
Why?
|
| Exodeoxyribonucleases | 1 | 2009 | 180 | 0.020 |
Why?
|
| Heat-Shock Proteins | 1 | 1992 | 822 | 0.020 |
Why?
|
| Transcriptional Elongation Factors | 1 | 2009 | 166 | 0.020 |
Why?
|
| Leukemia Virus, Murine | 1 | 1988 | 117 | 0.020 |
Why?
|
| beta 2-Microglobulin | 1 | 2008 | 315 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 625 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 1998 | 2635 | 0.020 |
Why?
|
| Treatment Failure | 1 | 1993 | 2618 | 0.020 |
Why?
|
| Formaldehyde | 1 | 1989 | 353 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2016 | 2440 | 0.020 |
Why?
|
| Biopsy, Needle | 2 | 1992 | 1641 | 0.020 |
Why?
|
| Desmosomes | 1 | 1987 | 73 | 0.020 |
Why?
|
| Quinazolines | 1 | 2013 | 1356 | 0.020 |
Why?
|
| Cohort Studies | 4 | 2010 | 40561 | 0.020 |
Why?
|
| Rats | 4 | 2007 | 24260 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2011 | 2557 | 0.020 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2007 | 258 | 0.020 |
Why?
|
| Proportional Hazards Models | 2 | 2008 | 12354 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 3870 | 0.020 |
Why?
|
| Lysosomes | 1 | 2011 | 893 | 0.020 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1987 | 821 | 0.020 |
Why?
|
| Treatment Outcome | 5 | 2013 | 63114 | 0.020 |
Why?
|
| Time Factors | 5 | 2013 | 40075 | 0.020 |
Why?
|
| Protein Transport | 1 | 2012 | 1988 | 0.020 |
Why?
|
| Histones | 1 | 1996 | 2599 | 0.020 |
Why?
|
| Uniparental Disomy | 1 | 2006 | 43 | 0.020 |
Why?
|
| I-kappa B Kinase | 1 | 2007 | 252 | 0.020 |
Why?
|
| Gene Deletion | 1 | 1994 | 2751 | 0.020 |
Why?
|
| Amylases | 1 | 1986 | 173 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 6489 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2016 | 35421 | 0.020 |
Why?
|
| Genes, X-Linked | 1 | 2006 | 128 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 1998 | 4456 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 2010 | 1227 | 0.020 |
Why?
|
| Dexamethasone | 1 | 1992 | 1951 | 0.020 |
Why?
|
| Protein Binding | 2 | 2012 | 9386 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2006 | 299 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 1999 | 2734 | 0.020 |
Why?
|
| Esophageal Neoplasms | 1 | 1995 | 1583 | 0.020 |
Why?
|
| Adaptation, Physiological | 1 | 2012 | 1312 | 0.020 |
Why?
|
| Chromosome Mapping | 3 | 2004 | 4740 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2006 | 411 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 2727 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 1996 | 365 | 0.020 |
Why?
|
| Cell Nucleus | 2 | 2006 | 2969 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 4751 | 0.020 |
Why?
|
| Prospective Studies | 4 | 2015 | 53288 | 0.020 |
Why?
|
| Body Fluids | 1 | 1986 | 319 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 1992 | 1988 | 0.010 |
Why?
|
| Automation | 1 | 2006 | 584 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1988 | 1369 | 0.010 |
Why?
|
| DNA Copy Number Variations | 1 | 2012 | 1941 | 0.010 |
Why?
|
| Neuroblastoma | 1 | 1992 | 1226 | 0.010 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 1986 | 504 | 0.010 |
Why?
|
| Survival Rate | 2 | 1995 | 12788 | 0.010 |
Why?
|
| Restriction Mapping | 2 | 1995 | 878 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 1992 | 3420 | 0.010 |
Why?
|
| Pleural Effusion | 1 | 1986 | 338 | 0.010 |
Why?
|
| Smoking | 3 | 1995 | 8987 | 0.010 |
Why?
|
| Endometrial Neoplasms | 1 | 1992 | 1353 | 0.010 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1992 | 1363 | 0.010 |
Why?
|
| Heterochromatin | 1 | 2005 | 296 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2004 | 403 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2004 | 354 | 0.010 |
Why?
|
| RNA, Untranslated | 1 | 2006 | 453 | 0.010 |
Why?
|
| Fibroblasts | 1 | 1992 | 4161 | 0.010 |
Why?
|
| Disease Models, Animal | 2 | 2013 | 18029 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1985 | 2645 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 6895 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1998 | 9959 | 0.010 |
Why?
|
| CpG Islands | 1 | 2006 | 1172 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2009 | 3846 | 0.010 |
Why?
|
| Surgical Procedures, Operative | 1 | 1993 | 1876 | 0.010 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2001 | 112 | 0.010 |
Why?
|
| Biological Transport | 1 | 2006 | 2118 | 0.010 |
Why?
|
| Oligonucleotide Probes | 2 | 1991 | 427 | 0.010 |
Why?
|
| Risk Factors | 4 | 2008 | 72290 | 0.010 |
Why?
|
| Species Specificity | 1 | 2005 | 2478 | 0.010 |
Why?
|
| Survival Analysis | 1 | 1993 | 10252 | 0.010 |
Why?
|
| Stromal Cells | 1 | 2006 | 1355 | 0.010 |
Why?
|
| Sarcoma | 1 | 1992 | 1897 | 0.010 |
Why?
|
| Risk Assessment | 2 | 1999 | 23338 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 2000 | 191 | 0.010 |
Why?
|
| Butadienes | 1 | 2000 | 110 | 0.010 |
Why?
|
| Upstream Stimulatory Factors | 1 | 1999 | 20 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 2000 | 158 | 0.010 |
Why?
|
| Retinoblastoma-Binding Protein 1 | 1 | 1999 | 142 | 0.010 |
Why?
|
| Transcription Factor DP1 | 1 | 1999 | 141 | 0.010 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2000 | 61 | 0.010 |
Why?
|
| Chromones | 1 | 2000 | 154 | 0.010 |
Why?
|
| Incidence | 2 | 2015 | 20947 | 0.010 |
Why?
|
| Helix-Loop-Helix Motifs | 1 | 1999 | 96 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2012 | 9734 | 0.010 |
Why?
|
| Family | 2 | 2002 | 3147 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1999 | 335 | 0.010 |
Why?
|
| E2F Transcription Factors | 1 | 1999 | 277 | 0.010 |
Why?
|
| Robotics | 1 | 2006 | 899 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 1988 | 2133 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2000 | 480 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2007 | 6386 | 0.010 |
Why?
|
| Isoquinolines | 1 | 2000 | 367 | 0.010 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 1998 | 102 | 0.010 |
Why?
|
| Androstadienes | 1 | 2000 | 346 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2000 | 489 | 0.010 |
Why?
|
| Recurrence | 1 | 2010 | 8340 | 0.010 |
Why?
|
| Cell Movement | 1 | 2010 | 5217 | 0.010 |
Why?
|
| Dimerization | 1 | 1999 | 893 | 0.010 |
Why?
|
| Linear Models | 1 | 2008 | 5952 | 0.010 |
Why?
|
| Respiratory System | 1 | 1981 | 557 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2007 | 2250 | 0.010 |
Why?
|
| Kinetics | 2 | 1995 | 6473 | 0.010 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2000 | 491 | 0.010 |
Why?
|
| Receptor, TIE-2 | 1 | 1998 | 178 | 0.010 |
Why?
|
| Male | 10 | 2007 | 350118 | 0.010 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2001 | 627 | 0.010 |
Why?
|
| Research Subjects | 1 | 1999 | 239 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2007 | 3494 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 1988 | 5524 | 0.010 |
Why?
|
| Immediate-Early Proteins | 1 | 1999 | 453 | 0.010 |
Why?
|
| Age Factors | 1 | 2013 | 18370 | 0.010 |
Why?
|
| Viral Envelope Proteins | 1 | 1999 | 635 | 0.010 |
Why?
|
| Registries | 2 | 2002 | 8089 | 0.010 |
Why?
|
| Thionucleotides | 1 | 1995 | 107 | 0.010 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2005 | 1861 | 0.010 |
Why?
|
| Epitopes | 2 | 1992 | 2571 | 0.010 |
Why?
|
| Protamine Kinase | 1 | 1994 | 12 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1995 | 378 | 0.010 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 1995 | 225 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 1995 | 377 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2000 | 1285 | 0.010 |
Why?
|
| Nitriles | 1 | 2000 | 956 | 0.010 |
Why?
|
| Mitosis | 1 | 2000 | 1208 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2013 | 12261 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2007 | 5985 | 0.010 |
Why?
|
| Fluorouracil | 2 | 1990 | 1619 | 0.010 |
Why?
|
| Poly A | 1 | 1994 | 185 | 0.010 |
Why?
|
| Educational Status | 1 | 2002 | 2540 | 0.010 |
Why?
|
| Breast Neoplasms, Male | 1 | 1995 | 210 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2008 | 5102 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2007 | 12245 | 0.010 |
Why?
|
| Kidney | 1 | 2009 | 7186 | 0.010 |
Why?
|
| Esophagogastric Junction | 1 | 1995 | 313 | 0.010 |
Why?
|
| DNA Replication | 1 | 2000 | 1399 | 0.010 |
Why?
|
| Tissue Embedding | 1 | 1992 | 43 | 0.010 |
Why?
|
| Paraffin Embedding | 1 | 1993 | 299 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 1998 | 1770 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1996 | 1950 | 0.010 |
Why?
|
| Endometrium | 1 | 1995 | 424 | 0.010 |
Why?
|
| Oligonucleotides | 1 | 1995 | 572 | 0.010 |
Why?
|
| Logistic Models | 1 | 2007 | 13408 | 0.010 |
Why?
|
| Neuraminidase | 1 | 1992 | 210 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2005 | 3647 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 1996 | 1526 | 0.010 |
Why?
|
| Freezing | 1 | 1992 | 303 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2007 | 4034 | 0.010 |
Why?
|
| Health Surveys | 1 | 2002 | 4037 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 1998 | 1434 | 0.010 |
Why?
|
| Tissue Fixation | 1 | 1992 | 241 | 0.010 |
Why?
|
| Drug Administration Schedule | 2 | 1990 | 4933 | 0.010 |
Why?
|
| Half-Life | 1 | 1992 | 661 | 0.010 |
Why?
|
| Anesthesia, General | 1 | 1998 | 1171 | 0.010 |
Why?
|
| Binding Sites | 1 | 1999 | 6114 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1991 | 803 | 0.010 |
Why?
|
| Neoplasm, Residual | 1 | 1995 | 973 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 1994 | 1202 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2006 | 13989 | 0.010 |
Why?
|
| Genotype | 1 | 2005 | 12951 | 0.010 |
Why?
|
| Cytological Techniques | 1 | 1992 | 219 | 0.010 |
Why?
|
| Codon | 1 | 1992 | 611 | 0.010 |
Why?
|
| Carbohydrates | 1 | 1992 | 394 | 0.010 |
Why?
|
| Leukopenia | 1 | 1990 | 212 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2000 | 6459 | 0.010 |
Why?
|
| Mammals | 1 | 1995 | 1143 | 0.010 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 1992 | 323 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1992 | 1801 | 0.010 |
Why?
|
| Trans-Activators | 1 | 1999 | 2924 | 0.010 |
Why?
|
| Methionine | 1 | 1992 | 590 | 0.010 |
Why?
|
| Cell Separation | 1 | 1995 | 1751 | 0.010 |
Why?
|
| Prevalence | 1 | 2006 | 15226 | 0.010 |
Why?
|
| ROC Curve | 1 | 1997 | 3527 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1994 | 1213 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1990 | 647 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1992 | 1799 | 0.010 |
Why?
|
| Tretinoin | 1 | 1992 | 517 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 1996 | 1741 | 0.010 |
Why?
|
| Methylnitronitrosoguanidine | 1 | 1988 | 20 | 0.010 |
Why?
|
| Endopeptidases | 1 | 1992 | 772 | 0.010 |
Why?
|
| Gene Rearrangement | 1 | 1994 | 1179 | 0.010 |
Why?
|
| 4-Nitroquinoline-1-oxide | 1 | 1988 | 20 | 0.010 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 1988 | 40 | 0.000 |
Why?
|
| Friend murine leukemia virus | 1 | 1988 | 65 | 0.000 |
Why?
|
| Sequence Analysis, DNA | 1 | 1999 | 4803 | 0.000 |
Why?
|
| Lymphocytes | 1 | 1996 | 2617 | 0.000 |
Why?
|
| Lung | 1 | 1987 | 9856 | 0.000 |
Why?
|
| Pain, Postoperative | 1 | 1998 | 1643 | 0.000 |
Why?
|
| Inflammation | 1 | 1987 | 10638 | 0.000 |
Why?
|
| United States | 1 | 2015 | 69872 | 0.000 |
Why?
|
| Colony-Forming Units Assay | 1 | 1987 | 356 | 0.000 |
Why?
|
| Rats, Inbred F344 | 1 | 1988 | 862 | 0.000 |
Why?
|
| Mucous Membrane | 1 | 1990 | 673 | 0.000 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1989 | 964 | 0.000 |
Why?
|
| Pilot Projects | 1 | 2000 | 8324 | 0.000 |
Why?
|
| Hot Temperature | 1 | 1992 | 1354 | 0.000 |
Why?
|
| Algorithms | 1 | 2006 | 13881 | 0.000 |
Why?
|
| Vincristine | 1 | 1987 | 1039 | 0.000 |
Why?
|
| Thymus Neoplasms | 1 | 1988 | 268 | 0.000 |
Why?
|
| Blood | 1 | 1987 | 598 | 0.000 |
Why?
|
| Cilia | 1 | 1989 | 466 | 0.000 |
Why?
|
| Length of Stay | 1 | 1998 | 6309 | 0.000 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1995 | 2752 | 0.000 |
Why?
|
| RNA | 1 | 1994 | 2749 | 0.000 |
Why?
|
| Methotrexate | 1 | 1990 | 1727 | 0.000 |
Why?
|
| Antigens, Viral | 1 | 1988 | 1035 | 0.000 |
Why?
|
| Cell Differentiation | 2 | 1992 | 11483 | 0.000 |
Why?
|
| Rabbits | 1 | 1989 | 4894 | 0.000 |
Why?
|
| Mass Screening | 1 | 1998 | 5255 | 0.000 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1988 | 1821 | 0.000 |
Why?
|
| Cross-Sectional Studies | 1 | 2001 | 25043 | 0.000 |
Why?
|
| Adolescent | 2 | 1992 | 85781 | 0.000 |
Why?
|
| Lymphoma | 1 | 1988 | 1877 | 0.000 |
Why?
|
| Protein Kinase Inhibitors | 1 | 1994 | 5535 | 0.000 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 1979 | 207 | 0.000 |
Why?
|
| Radiography | 1 | 1989 | 7023 | 0.000 |
Why?
|
| Chromosomes | 1 | 1979 | 596 | 0.000 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1988 | 10943 | 0.000 |
Why?
|
| Isoenzymes | 1 | 1979 | 1726 | 0.000 |
Why?
|
| Calcium | 1 | 1987 | 5756 | 0.000 |
Why?
|
| Mice, Inbred C57BL | 1 | 1988 | 21827 | 0.000 |
Why?
|
| Receptors, Cell Surface | 1 | 1979 | 2866 | 0.000 |
Why?
|